Versatile intact LC-MS method for evaluating the drug-antibody ratio and drug load distribution of antibody-drug conjugates in human plasma., PMID:40267607
A Recognition Tag of Human Origin for Bioorthogonal Generation of Antibody-Drug Conjugates using Microbial Biotin Ligase., PMID:40244636
NIR-II aza-BODIPY Platform for the Development of a Fluorescent Antibody Drug Conjugate., PMID:40152348
PK/PD of Positively Charged ADC in Mice., PMID:40143040
Receptor CDCP1 Is a Potential Target for Personalized Imaging and Treatment of Poor Outcome HER2+, Triple-Negative, and Metastatic ER+/HER2- Breast Cancers., PMID:39869307
Branched Linkers for Homogeneous Antibody-Drug Conjugates: How Long Is Long Enough?, PMID:39769122
PK/PD Evaluation of Antibody-Drug Conjugates with Enhanced Immune Effector Functions., PMID:39702683
One-Step Maleimide-Based Dual Functionalization of Protein N-Termini., PMID:39564713
Evaluation of Potency and Specificity of Cryptophycin-Loaded Antibody-Drug Conjugates., PMID:39462215
NSPs: chromogenic linkers for fast, selective, and irreversible cysteine modification., PMID:39027294
Dual-Targeting of the HER2 Cancer Receptor with an Antibody-Directed Enzyme and a Nanobody-Guided MMAE Prodrug Scaffold., PMID:38945824
Surface-Available HER2 Levels Alone Are Not Indicative of Cell Response to HER2-Targeted Antibody-Drug Conjugate Therapies., PMID:38931874
Biological Evaluation of Antibody-Drug Conjugates Produced by Tag-Free Lipoate Ligase A Modification., PMID:38350078
Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability., PMID:38324296
Branched pegylated linker-auristatin to control hydrophobicity for the production of homogeneous minibody-drug conjugate against HER2-positive breast cancer., PMID:38215985
Generation and Characterization of SORT1-Targeted Antibody-Drug Conjugate for the Treatment of SORT1-Positive Breast Tumor., PMID:38139459
RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: a real-world study., PMID:37946161
A Novel Dual-Payload ADC for the Treatment of HER2+ Breast and Colon Cancer., PMID:37631234
Tumor Site-Specific Cleavage Improves the Antitumor Efficacy of Antibody-Drug Conjugates., PMID:37446189
Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates Administered via Subcutaneous and Intratumoral Routes., PMID:37111619
Antitumor effect of a novel humanized MUC1 antibody-drug conjugate on triple-negative breast cancer., PMID:37089317
Phenyldivinylsulfonamides for the construction of antibody-drug conjugates with controlled four payloads., PMID:36924655
Payload-Binding Fab Fragments Increase the Therapeutic Index of MMAE Antibody-Drug Conjugates., PMID:36723609
A glyco-engineering approach for site-specific conjugation to Fab glycans., PMID:36447399
Physicochemical and biological impact of metal-catalyzed oxidation of IgG1 monoclonal antibodies and antibody-drug conjugates via reactive oxygen species., PMID:36151884
Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy., PMID:35506447
An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index., PMID:35422630
Therapeutic Potential of MF-TTZ-MMAE, a Site-Specifically Conjugated Antibody-Drug Conjugate, for the Treatment of HER2-Overexpressing Breast Cancer., PMID:35104102
Dual intra- and extracellular release of monomethyl auristatin E from a neutrophil elastase-sensitive antibody-drug conjugate., PMID:34974337
Antibody-drug conjugate and free geldanamycin combination therapy enhances anti-cancer efficacy., PMID:34763035
Pharmacokinetics of Monoclonal Antibody and Antibody Fragments in the Mouse Eye Following Systemic Administration., PMID:34750690
Simulating the Selection of Resistant Cells with Bystander Killing and Antibody Coadministration in Heterogeneous Human Epidermal Growth Factor Receptor 2-Positive Tumors., PMID:34649966
A novel humanized MUC1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer., PMID:34586349
Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors., PMID:34532642
Purification and In Vitro Evaluation of an Anti-HER2 Affibody-Monomethyl Auristatin E Conjugate in HER2-Positive Cancer Cells., PMID:34439990
Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody-Drug Conjugate Exposure in Solid Tumor., PMID:33856579
Divinylsulfonamides enable the construction of homogeneous antibody-drug conjugates., PMID:33039798
Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs)., PMID:32889587
On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency., PMID:32376903
Evolution of the Systems Pharmacokinetics-Pharmacodynamics Model for Antibody-Drug Conjugates to Characterize Tumor Heterogeneity and In Vivo Bystander Effect., PMID:32273304
Evaluation of Quantitative Relationship Between Target Expression and Antibody-Drug Conjugate Exposure Inside Cancer Cells., PMID:32086295
Sulfatase-cleavable linkers for antibody-drug conjugates., PMID:34084399
Antibody Coadministration as a Strategy to Overcome Binding-Site Barrier for ADCs: a Quantitative Investigation., PMID:31938899
Binding and functional profiling of antibody mutants guides selection of optimal candidates as antibody drug conjugates., PMID:31891584
Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability., PMID:31597712
Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues., PMID:31358513
Synthesis and Enhanced Cellular Uptake In Vitro of Anti-HER2 Multifunctional Gold Nanoparticles., PMID:31234432
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer., PMID:30841523
A Cell-Level Systems PK-PD Model to Characterize In Vivo Efficacy of ADCs., PMID:30823607
A "Dual" Cell-Level Systems PK-PD Model to Characterize the Bystander Effect of ADC., PMID:30790581
For research use only. Not for human or drug use.
